MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype

J Clin Oncol. 2020 Nov 10;38(32):3731-3734. doi: 10.1200/JCO.20.02190. Epub 2020 Sep 8.

Authors

David M Gershenson¹, Charlie Gourley², James Paul³

Affiliations

¹ Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
² Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
³ Cancer Research UK Clinical Trials Unit, University of Glasgow, Glasgow, United Kingdom.

PMID: 32897828
DOI: 10.1200/JCO.20.02190

No abstract available

Publication types

Editorial
Comment

MeSH terms

Benzimidazoles
Cystadenocarcinoma, Serous* / drug therapy
Fallopian Tubes
Female
Humans
Mitogen-Activated Protein Kinase Kinases
Ovarian Neoplasms* / drug therapy
Peritoneum
Physicians*

Substances

Benzimidazoles
binimetinib
Mitogen-Activated Protein Kinase Kinases